David Stevens

Dr. David Stevens

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DSDavid Stevens
David Stevens
RMRichard B Moss
Richard B Moss
VKViswanath P. Kurup
Viswanath P. Kurup
AKAlan P. Knutsen
Alan P. Knutsen
PGPaul Greenberger
Paul Greenberger
PCParticipants In The Cystic Fibrosis Foundation Consensus Conference
Participants In The Cystic Fibrosis Foundation Consensus Conference
Because of the difficulties of recognizing allergic bronchopulmonary aspergillosis (ABPA) in the context of cystic fibrosis (because of overlapping c

1 June 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLouis D. Saravolatz
Louis D. Saravolatz
SDStanley C. Deresinski
Stanley C. Deresinski
DSDavid Stevens
David Stevens
Caspofungin, the first inhibitor of fungal β-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective

15 January 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JLJuergen Loeffler
Juergen Loeffler
DSDavid Stevens
David Stevens
The increasing incidence of invasive fungal infections is the result of many factors, including an increasing number of patients with severe immunosu

1 September 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
DSDavid Stevens
David Stevens
MEMarife Espiritu
Marife Espiritu
RPRachana Parmar
Rachana Parmar
Resistance problems with caspofungin, an echinocandin inhibitor of fungal cell wall glucan synthesis, have been rare. We noted paradoxical turbid growth of Candida albicans isolates in broth in some high (supra-MIC) concentrations. Among isolates submitted for susceptibility testing and screened at drug concentrations up to 12.5 μg/ml, the frequency was 16%. Analysis of the turbid growth indicated slowing of growth in the presence of drug but with numbers of CFU up to 72% those of drug-free controls. Clearing of growth again by the highest drug concentrations produced a quadriphasic pattern in a tube dilution series. Cells growing at high drug concentrations were not resistant on retesting but showed the paradoxical effect of the parent. Among a selected series of isolates tested at concentrations up to 50 μg/ml, an additional 53% showed a “mini-paradoxical effect”: no turbid growth but incomplete killing at high concentrations (supra-minimum fungicidal concentration). These effects were reproducible; medium dependent in extent; noted in macro- and microdilution, in the presence or absence of serum, and on agar containing drug (but not when drug concentrations were not constant, as in agar diffusion); not seen with other echinocandins and less commonly in other Candida species; and not due to destruction of drug in tubes showing the effect. Cooperative enhancement of inhibition by a second drug could eradicate the effect. We postulate that high drug concentrations derepress or activate resistance mechanisms. The abilities of subpopulations to survive at high drug concentrations could have in vivo consequences.

1 September 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
DSDavid Stevens
David Stevens
MIMasayuki Ichinomiya
Masayuki Ichinomiya
YKYukako Koshi
Yukako Koshi
HHHiroyuki Horiuchi
Hiroyuki Horiuchi
Concentrations above the MIC of caspofungin allow growth of some Candida isolates. A strain demonstrating paradoxical growth was grown in the presence and absence of caspofungin, and the cell wall content was analyzed. β-1,3-Glucan declined 81% in the presence of caspofungin, as expected. β-1,6-Glucan declined 73%. Chitin increased 898%, demonstrating a mechanism for paradoxical growth—a rapid shift in the key polymer.

1 January 2018 in Journal of Bacteriology
Verified
Journal Article
Open access
PDF file
GSGabriele Sass
Gabriele Sass
HNHasan Nazik
Hasan Nazik
JPJohn Penner
John Penner
HSHemi Shah
Hemi Shah
SAShajia Rahman Ansari
Shajia Rahman Ansari
DSDavid Stevens
David Stevens
Pseudomonas aeruginosa and Aspergillus fumigatus are common opportunistic bacterial and fungal pathogens, respectively. They often coexist in airways of immunocompromised patients and individuals with cystic fibrosis, where they form biofilms and cause acute and chronic illnesses. Hence, the interactions between them have long been of interest and it is known that P. aeruginosa can inhibit A. fumigatus in vitro . We have approached the definition of the inhibitory P. aeruginosa molecules by studying 24 P. aeruginosa mutants with various virulence genes deleted for the ability to inhibit A. fumigatus biofilms. The ability of P. aeruginosa cells or their extracellular products produced during planktonic or biofilm growth to affect A. fumigatus biofilm metabolism or planktonic A. fumigatus growth was studied in agar and liquid assays using conidia or hyphae. Four mutants, the pvdD pchE , pvdD , lasR rhlR , and lasR mutants, were shown to be defective in various assays. This suggested the P. aeruginosa siderophore pyoverdine as the key inhibitory molecule, although additional quorum sensing-regulated factors likely contribute to the deficiency of the latter two mutants. Studies of pure pyoverdine substantiated these conclusions and included the restoration of inhibition by the pyoverdine deletion mutants. A correlation between the concentration of pyoverdine produced and antifungal activity was also observed in clinical P. aeruginosa isolates derived from lungs of cystic fibrosis patients. The key inhibitory mechanism of pyoverdine was chelation of iron and denial of iron to A. fumigatus . IMPORTANCE Interactions between human pathogens found in the same body locale are of vast interest. These interactions could result in exacerbation or amelioration of diseases. The bacterium Pseudomonas aeruginosa affects the growth of the fungus Aspergillus fumigatus . Both pathogens form biofilms that are resistant to therapeutic drugs and host immunity. P. aeruginosa and A. fumigatus biofilms are found in vivo , e.g., in the lungs of cystic fibrosis patients. Studying 24 P. aeruginosa mutants, we identified pyoverdine as the major anti- A. fumigatus compound produced by P. aeruginosa . Pyoverdine captures iron from the environment, thus depriving A. fumigatus of a nutrient essential for its growth and metabolism. We show how microbes of different kingdoms compete for essential resources. Iron deprivation could be a therapeutic approach to the control of pathogen growth.